Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer



Status:Recruiting
Conditions:Colorectal Cancer, Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:November 7, 2017
End Date:April 30, 2022

Use our guide to learn which trials are right for you!

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

This randomized phase III trial studies how well combination chemotherapy, bevacizumab,
and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA)
mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in
chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as bevacizumab and atezolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving combination
chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with
colorectal cancer.

PRIMARY OBJECTIVES:

I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil,
oxaliplatin, and leucovorin calcium (mFOLFOX6)/bevacizumab plus atezolizumab (combination)
and atezolizumab (single agent) as compared to mFOLFOX6/bevacizumab (control).

SECONDARY OBJECTIVES:

I. To compare the overall survival. II. To compare the objective response rates (ORR) per
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

III. To determine the safety profiles of the combination of mFOLFOX6/bevacizumab/atezolizumab
and atezolizumab monotherapy in patients with mismatch-repair deficient (dMMR) metastatic
colorectal cancer (mCRC).

IV. To compare the surgical conversion rate. V. To compare disease control rate (complete
response [CR] + partial response [PR] + stable disease [SD]) at 12 months.

VI. To determine the duration of response and stable disease. VII. To determine the
progression-free survival (PFS) by retrospective central independent scan review.

EXPLORATORY OBJECTIVES:

I. To compare the health-related quality of life and patient-reported symptoms.

TRANSLATIONAL OBJECTIVES:

I. To bank tissue and blood samples for other future correlative studies from patients
enrolled on the study.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1,
oxaliplatin IV over 2 hours on day 1 of courses 1-10, leucovorin calcium IV over 2 hours on
day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin
repeats every 2 weeks for up to 10 courses in the absence of disease progression or
unacceptable toxicity. Courses of bevacizumab, leucovorin calcium, and fluorouracil repeat
every 2 weeks in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every
2 weeks for up to 48 courses in the absence of disease progression or unacceptable toxicity.

ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats
every 2 weeks for up to 48 courses in the absence of disease progression or unacceptable
toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV
over 2 hours on day 1 courses 1-10, leucovorin calcium IV over 2 hours on day 1, and
fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks
for up to 10 courses in the absence of disease progression or unacceptable toxicity. Courses
of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of
disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 8 weeks for 18 months,
and then every 12 weeks for up to 5 years.

Inclusion Criteria:

- The patient must have signed and dated an Institutional Review Board (IRB)-approved
consent form that conforms to federal and institutional guidelines

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

- Diagnosis of metastatic adenocarcinoma of colon or rectum without previous
chemotherapy or any other systemic therapy for metastatic colorectal cancer

- Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory
Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all
four IHC markers, including MLH1, MSH2, PMS2, and MSH6; Note: microsatellite
instability high (MSI-H) diagnosed by microsatellite instability (MSI) testing (either
Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) is not
eligible unless dMMR is confirmed by CLIA-certified immunohistochemical (IHC) assay
with a panel of all four IHC markers including MLH1, MSH2, PMS2 and MSH6

- An adequate amount of archived tumor tissue, either from primary colorectal cancer
site or metastatic lesions, for central confirmation of dMMR status:

- Either whole or part of the formalin-fixed paraffin-embedded (FFPE) block
containing tumor tissue; or

- At least 9 unstained slides containing tumor sections

- Documentation by positron emission tomography(PET)/computed tomography (CT) scan, CT
scan, or magnetic resonance imaging (MRI) that the patient has untreated measurable
metastatic disease per RECIST 1.1

- No immediate need for surgical intervention for the primary tumor or palliative
diversion/bypass

- Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior
randomization)

- Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)

- Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)

- Total bilirubin must be =< 1.5 x ULN (upper limit of normal) for the lab unless the
patient has a bilirubin elevation > 1.5 x ULN to 3 x ULN due to Gilbert's disease or
similar syndrome involving slow conjugation of bilirubin (obtained within 28 days
prior randomization); and

- Alkaline phosphatase must be =< 2.5 x ULN for the lab with the following exception:
patients with documented liver metastases or bone involvement - alkaline phosphatase
must be =< 5 x ULN (obtained within 28 days prior randomization); and

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN
for the lab with the following exception: for patients with documented liver
metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior
randomization)

- Serum creatinine =< 1.5 x ULN for the lab or measured or calculated creatinine
clearance >= 30 mL/min (obtained within 28 days prior randomization)

- A urine sample tested for proteinuria by the dipstick method must indicate 0 -1+
protein; if dipstick reading is >= 2+, a 24-hour urine specimen must demonstrate < 1.0
g of protein per 24 hours

- International normalized ratio of prothrombin time (INR) and prothrombin time (PT)
must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are
therapeutically treated with an agent such as warfarin may participate if they are on
a stable dose and no underlying abnormality in coagulation parameters exists per
medical history

- Pregnancy test done within 14 days prior randomization must be negative (for women of
childbearing potential only); pregnancy testing should be performed according to
institutional standards; should a woman become pregnant or suspect she is pregnant
while she or her partner is participating in this study, she should inform her
treating physician immediately

- Women of child-bearing potential must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry, for the duration of
study participation, and for 5 months (150 days) after the last dose of atezolizumab,
6 months after the last dose of bevacizumab, and 6 months after the last dose of
mFOLFOX6; men with female partners of child-bearing potential must agree to use
adequate contraception prior to the study, for the duration of study participation,
and for 6 months after the last dose of bevacizumab and 6 months after the last dose
of mFOLFOX6

Exclusion Criteria:

- Patients with central nervous system (CNS) metastases are excluded, with the following
exceptions:

- Patients with asymptomatic untreated CNS metastases may be enrolled, provided all
eligibility criteria are met, as well as the following:

- Evaluable or measurable disease outside the CNS

- No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within
10 mm of the optic apparatus (optic nerves and chiasm)

- No history of intracranial hemorrhage or spinal cord hemorrhage

- No ongoing requirement for dexamethasone for CNS disease; patients on a
stable dose of anticonvulsants are permitted.

- No neurosurgical resection or brain biopsy within 28 days prior to
randomization

- Patients with asymptomatic treated CNS metastases may be enrolled, provided all
eligibility criteria are met, as well as the following:

- Radiographic demonstration of improvement upon the completion of
CNS-directed therapy and no evidence of interim progression between the
completion of CNS-directed therapy and the screening radiographic study

- No stereotactic radiation or whole-brain radiation within 28 days prior to
randomization

- Screening CNS radiographic study >= 28 days from completion of radiotherapy
and >= 14 days from discontinuation of corticosteroids

- Known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin

- Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or
diastolic BP 90 mmHg with or without anti-hypertensive medication; patients with
initial BP elevations are eligible if initiation or adjustment of BP medication lowers
pressure to meet entry criteria

- Any of the following cardiac conditions:

- Documented New York Heart Association (NYHA) class III or IV congestive heart
failure

- Myocardial infarction within 6 months prior to randomization

- Unstable angina within 6 months prior to randomization

- Symptomatic arrhythmia

- Serious or non-healing wound, skin ulcer, or bone fracture

- History of transient ischemic attack (TIA), cerebrovascular accident (CVA),
gastrointestinal (GI) perforation or arterial thrombotic event within 6 months prior
to randomization or symptomatic peripheral ischemia

- Other malignancies are excluded unless the patient has completed therapy for the
malignancy >= 12 months prior to randomization and is considered disease-free;
patients with the following cancers are eligible if diagnosed and treated within the
past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the
skin

- Known DPD (dihydro pyrimidine dehydrogenase) deficiency

- Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for
Adverse Events [CTCAE] version [v] 5.0) in patients with no prior oxaliplatin therapy

- Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization

- Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or
pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4
may be enrolled provided the following requirements are met:

- Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the
last dose to randomization

- No history of severe immune-related adverse effects (CTCAE Grade 3 and 4) from
anti-CTLA-4

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events (other than alopecia) due to agents administered more
than 4 weeks earlier are excluded; however, the following therapies are allowed:

- Hormone-replacement therapy or oral contraception

- Herbal therapy > 7 days prior to randomization (herbal therapy intended as
anticancer therapy must be discontinued at least 1 week prior to randomization)

- Palliative radiotherapy for bone metastases > 14 days prior to randomization

- Treatment with systemic immunostimulatory medications (including, but not limited to
interferon [IFN]-alpha or interleukin [IL]-2 within 42 days prior to randomization

- Treatment with systemic immunosuppressive medications (including, but not limited to,
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,

- Patients who have received acute, low dose, systemic immunosuppressant
medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily
treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone
equivalent) may be enrolled

- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone)
for patients with orthostatic hypotension or adrenocortical insufficiency is
allowed

- Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of
bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is
allowed

- Patients requiring treatment with a receptor activator of nuclear factor kappa-B
ligand (RANKL) inhibitor (e.g., denosumab) who cannot discontinue it before treatment
with atezolizumab

- Treatment with any other investigational agent within 4 weeks prior to randomization

- Known clinically significant liver disease, including active viral, alcoholic, or
other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,

- Patients with past or resolved hepatitis B infection (defined as having a
negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc
[antibody to hepatitis B core antigen] antibody test) are eligible

- Patients positive for hepatitis C virus (HCV) antibody are eligible only if
polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)

- History or risk of autoimmune disease, including, but not limited to, systemic lupus
erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis
associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's
syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune
thyroid disease, vasculitis, or glomerulonephritis; however,

- Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid
replacement hormone may be eligible

- Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may
be eligible

- Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with
dermatologic manifestations only (e.g., patients with psoriatic arthritis would
be excluded) are permitted provided that they meet the following conditions:

- Patients with psoriasis must have a baseline ophthalmologic exam to rule out
ocular manifestations

- Rash must cover less than 10% of body surface area (BSA)

- Disease is well controlled at baseline and only requiring low potency
topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%,
fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)

- No acute exacerbations of underlying condition within the last 12 months
(not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate,
retinoids, biologic agents, oral calcineurin inhibitors; high potency or
oral steroids)

- History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing
pneumonia, etc.), or evidence of active pneumonitis on screening chest computed
tomography (CT) scan; history of radiation pneumonitis in the radiation field
(fibrosis) is permitted

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins

- Patients with known active tuberculosis (TB) are excluded

- Severe infections within 28 days prior to randomization, including but not limited to,
hospitalization for complications of infection, bacteremia, or severe pneumonia

- Signs or symptoms of infection within 14 days prior to randomization

- Received oral or intravenous (IV) antibiotics within 14 days prior to randomization;
patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract
infection or chronic obstructive pulmonary disease) are eligible

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to randomization or anticipation of need for a major surgical procedure during
the course of the study

- Administration of a live, attenuated vaccine within 28 days prior to randomization or
anticipation that such a live, attenuated vaccine will be required during the study
and up to 5 months after the last dose of atezolizumab; Note: influenza vaccination
should be given during influenza season only (approximately October to March);
patients must not receive live, attenuated influenza vaccine within 28 days prior to
randomization or at any time during the study

- Psychiatric illness/social situations that would limit compliance with study
requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with atezolizumab; (Note: pregnancy testing should be performed
within 14 days prior to randomization according to institutional standards for women
of childbearing potential)

- Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this
study, but HIV-positive patients must have:

- A stable regimen of highly active anti-retroviral therapy (HAART); and

- No requirement for concurrent antibiotics or antifungal agents for the prevention
of opportunistic infections; and

- A CD4 count above 250 cells/uL and an undetectable HIV viral load on standard
PCR-based tests

- Patients with prior allogeneic bone marrow transplantation or prior solid organ
transplantation
We found this trial at
303
sites
Greenville, South Carolina 29615
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Peter Rubin
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
?
mi
from
Augusta, ME
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Patrick M. Boland
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Dan S. Zuckerman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Khalid Matin
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
?
mi
from
Akron, OH
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 715-623-9869
?
mi
from
Antigo, WI
Click here to add this to my saved trials
1506 South Oneida Street
Appleton, Wisconsin 54915
Principal Investigator: Kamal K. Abbi
Phone: 920-831-8900
?
mi
from
Appleton, WI
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Alexis D. Leal
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21244
Principal Investigator: Leon C. Hwang
Phone: 301-816-7218
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Bay City, Michigan 48706
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
?
mi
from
Bay City, MI
Click here to add this to my saved trials
Beaufort, South Carolina 29902
Principal Investigator: Majd Chahin
Phone: 843-522-7819
?
mi
from
Beaufort, SC
Click here to add this to my saved trials
Beaumont, Texas 77701
Principal Investigator: Ernest Hymel
Phone: 409-212-5956
?
mi
from
Beaumont, TX
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Sheikh Asim Ali
Phone: 412-339-5294
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bettendorf, Iowa 52722
Principal Investigator: Saima Sharif
Phone: 563-355-7733
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Biddeford, Maine 04005
Principal Investigator: Peter Rubin
?
mi
from
Biddeford, ME
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
43097 Woodward Avenue
Bloomfield, Michigan 48302
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
?
mi
from
Bloomfield, MI
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Dan S. Zuckerman
Phone: 412-339-5294
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Boone, IA
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
?
mi
from
Brewer, ME
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
?
mi
from
Bristol, TN
Click here to add this to my saved trials
Bristol, Virginia 24201
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
?
mi
from
Bristol, VA
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Haythem Y. Ali
Phone: 313-916-3721
?
mi
from
Brownstown, MI
Click here to add this to my saved trials
Burke, Virginia 22015
Principal Investigator: Leon C. Hwang
?
mi
from
Burke, VA
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Hanna K. Sanoff
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
Principal Investigator: Steven J. Jubelirer
Phone: 304-388-9944
?
mi
from
Charleston, WV
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Cheyenne, WY
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: William T. Leslie
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
?
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Jordan Kharofa
Phone: 513-558-4553
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
?
mi
from
Clarkston, MI
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Clarkston, MI
Click here to add this to my saved trials
31500 Telegraph Road
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Clarkston, MI
Click here to add this to my saved trials
Clinton Township, Michigan 48038
Principal Investigator: Haythem Y. Ali
Phone: 313-916-3721
?
mi
from
Clinton Township, MI
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Clive, IA
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Cody, WY
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
1500 West Poplar Avenue
Collierville, Tennessee 38017
Principal Investigator: Shailesh R. Satpute
Phone: 901-226-1366
?
mi
from
Collierville, TN
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
Principal Investigator: Alexis D. Leal
Phone: 719-365-2406
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbus, Ohio 43213
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Columbus, Ohio 43222
Principal Investigator: Timothy D. Moore
Phone: 614-234-5433
?
mi
from
Columbus, OH
Click here to add this to my saved trials
5100 W Broad St
Columbus, Ohio 43228
(614) 544-1000
Principal Investigator: Timothy D. Moore
Phone: 614-566-3275
Doctors Hospital Nationally recognized for care quality and patient safety and satisfaction, Doctors Hospital is...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
810 Jasonway Avenue
Columbus, Ohio 43214
614/442-3130
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Columbus Oncology and Hematology Associates Inc Columbus Oncology and Hematology Associates is a group of...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
111 S Grant Ave
Columbus, Ohio 43215
(614) 566-9000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Grant Medical Center Founded in 1900 in Columbus' downtown, Grant has grown into one of...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: John L. Hays
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Concord, California 94520
Principal Investigator: Gigi Q. Chen
Phone: 925-674-2580
?
mi
from
Concord, CA
Click here to add this to my saved trials
Danbury, Connecticut 06810
Principal Investigator: Wenli GaO
Phone: 203-739-8074
?
mi
from
Danbury, CT
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Suparna Mantha
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
1 Wyoming St,
Dayton, Ohio 45409
(937) 208-8000
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dearborn, Michigan 48126
Principal Investigator: Haythem Y. Ali
Phone: 313-916-3721
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Decatur, IL
Click here to add this to my saved trials
561 West Central Avenue
Delaware, Ohio 43015
(740) 615-1000
Principal Investigator: Timothy D. Moore
Phone: 740-615-0227
Delaware Health Center-Grady Cancer Center As the center of healthcare in Delaware County, Grady Memorial...
?
mi
from
Delaware, OH
Click here to add this to my saved trials
561 W. Central Avenue
Delaware, Ohio 43015
(740) 615-1000
Principal Investigator: Timothy D. Moore
Phone: 740-615-2403
Grady Memorial Hospital As the center of healthcare in Delaware County, Grady Memorial Hospital is...
?
mi
from
Delaware, OH
Click here to add this to my saved trials
Denver, Colorado 80206
Principal Investigator: Keren Sturtz
Phone: 877-225-5654
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
777 Bannock St
Denver, Colorado 80204
(303) 436-6000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Des Moines, Iowa 50309
Principal Investigator: Robert J. Behrens
Phone: 515-282-2921
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Robert J. Behrens
Phone: 515-282-2200
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Haythem Y. Ali
Phone: 313-916-3721
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials